Stockholm - Delayed Quote SEK
Double Bond Pharmaceutical Int. (DBP-B.ST)
0.2860
+0.0130
+(4.76%)
At close: April 25 at 2:39:24 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,089.1820
1,089.1820
1,370.3270
1,242.8850
956.2550
Cost of Revenue
696.0720
696.0720
4,675.7840
8,700.0670
11,187.4630
Gross Profit
393.1100
393.1100
-3,305.4570
-7,457.1820
-10,231.2080
Operating Expense
8,147.1600
8,147.1600
10,130.5310
7,703.5350
-974.9130
Operating Income
-7,754.0500
-7,754.0500
-13,435.9880
-15,160.7170
-9,256.2950
Net Non Operating Interest Income Expense
-172.8220
-172.8220
-114.2570
0.3060
-0.5690
Pretax Income
-13,241.9970
-13,241.9970
-17,337.9220
-15,160.4110
-9,256.8630
Net Income Common Stockholders
-13,241.9970
-13,241.9970
-17,337.9220
-15,160.4110
-9,256.8630
Diluted NI Available to Com Stockholders
-13,241.9970
-13,241.9970
-17,337.9220
-15,160.4110
-9,256.8630
Basic EPS
-0.13
-0.13
-0.19
-0.20
-0.14
Diluted EPS
-0.13
-0.13
-0.19
-0.20
-0.14
Basic Average Shares
101,861.5150
101,861.5150
91,252.2210
75,398.0640
65,867.1690
Diluted Average Shares
107,120.1080
101,861.5150
91,252.2210
75,398.0640
65,867.1690
Total Operating Income as Reported
--
--
-13,435.9880
-15,160.7180
-9,256.2950
Total Expenses
8,843.2320
8,843.2320
14,806.3150
16,403.6020
10,212.5500
Net Income from Continuing & Discontinued Operation
-13,241.9970
-13,241.9970
-17,337.9220
-15,160.4110
-9,256.8630
Normalized Income
-7,926.8720
-7,926.8720
-13,550.2450
-15,160.4110
-9,256.8630
Interest Income
0.1740
0.1740
0.2020
0.3320
--
Interest Expense
172.9960
172.9960
114.4590
0.0260
0.5690
Net Interest Income
-172.8220
-172.8220
-114.2570
0.3060
-0.5690
EBIT
-13,069.0010
-13,069.0010
-17,223.4630
-15,160.3850
-9,256.2940
EBITDA
-12,889.7580
-12,889.7580
-17,030.5820
-14,967.5040
-9,085.1570
Reconciled Cost of Revenue
696.0720
696.0720
4,675.7840
8,700.0670
11,187.4630
Reconciled Depreciation
179.2430
179.2430
192.8810
192.8810
171.1370
Net Income from Continuing Operation Net Minority Interest
-13,241.9970
-13,241.9970
-17,337.9220
-15,160.4110
-9,256.8630
Total Unusual Items Excluding Goodwill
-5,315.1250
-5,315.1250
-3,787.6770
--
--
Total Unusual Items
-5,315.1250
-5,315.1250
-3,787.6770
--
--
Normalized EBITDA
-7,574.6330
-7,574.6330
-13,242.9050
-14,967.5040
-9,085.1570
12/31/2021 - 7/10/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade